A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
12/2001
12/05/2001	EP0830448A4 Continuous selective clonogenic expansion of relatively undifferentiated cells
12/05/2001	EP0814815A4 Poly(hydroxy acid)/polymer conjugates for skin applications
12/05/2001	EP0789687B1 Ep2-receptor agonists as agents for lowering intraocular pressure
12/05/2001	EP0721337B1 Oral formulations of an antifungal
12/05/2001	EP0710112B1 Use of vitamin D and derivatives thereof for the manufacture of a medicament for protection against neuron loss
12/05/2001	EP0445255B2 USE OF HYALURONIC ACID IN COMBINATION WITH ASCORBIC ACID, ANTITUMOUR AGENTS AND/OR NSAIDs FOR TREATING CANCER
12/05/2001	CN1325450A Adenovirus-mediated gene therapy
12/05/2001	CN1325407A Platelet-derived growth factor D, DNA coding therefor and uses thereof
12/05/2001	CN1325403A Bile-acid substituted phenyl-alkenoylguanidines, method for the production thereof, use thereof as medicaments or diaymostic agents and medicaments that contain
12/05/2001	CN1325376A Novel compounds and medicinal use thereof
12/05/2001	CN1325308A Use of neurotrophic factor stimulators for treatment of ophthalmic neurodegenerative diseases
12/05/2001	CN1325304A 5HT1 receptor agonists and metoclopramide for treatment of migraine
12/05/2001	CN1325299A Orally administered controlled drug delivery system providing temporal and spatial control
12/05/2001	CN1325291A Anti-inflammatory and antimicrobial uses for bioactive glass compositions
12/05/2001	CN1325271A Compositions of restricted cells capable of rapid growth which produce proliferation suppressive materials, and uses thereof
12/05/2001	CN1325266A Disposable premoistened wipe containing an antimicrobial protease inhibitor
12/05/2001	CN1324607A Anti-fungus agent for local treatment of fungus infection of finger and its peripheral tissue and controllable releasable system of keratin-dissolving agnt
12/05/2001	CN1075816C Methods for in vivo reduction of nitric oxide levels and compositions sueful therefor
12/04/2001	US6326390 Use of adenosine A3 receptor antagonists to inhibit tumor growth
12/04/2001	US6326389 Administering sodium channel modulators
12/04/2001	US6326385 Administering poltassium channel modulator
12/04/2001	US6326383 Emesis therapy
12/04/2001	US6326370 Use of agonists or antagonists of P2 purinoceptors for the prevention of glutamate-evoked cytotoxicity
12/04/2001	US6326355 Method for the prevention and treatment of cachexia and anorexia
12/04/2001	US6326207 Human sodium-dependent phosphate cotransporter
12/04/2001	US6326170 Prokaryotic polynucleotides, polypeptides and their uses
12/04/2001	US6326162 Assays and peptide substrate for determining aggrecan degrading metallo protease activity
12/04/2001	US6326151 Screening methods to identify agents that selectively inhibit hepatitis C virus replication
12/04/2001	US6326034 From yeast or saltbush; regulate glucose and lipid metabolism, insulin; treatment of diabetes, cardiovascular diseases and hyperlipidemia; nontoxic
12/04/2001	US6326023 Synergistic anti-malarial formulation
12/04/2001	US6326009 Parenterally administering carbohydrate antigenic primer (determinant) bearing antigen; conjugated to animmunogenic carrier
12/04/2001	US6325998 Methods of treating disease using recombinant adeno-associated virus virions administered to muscle
12/04/2001	CA2229814C Peripherally active anti-hyperalgesic opiates
12/04/2001	CA2217953C A pharmaceutical composition containing n-chlorophenylcarbamates and n-chlorophenylthiocarbamates for inhibiting the growth of viruses and cancers
12/04/2001	CA2208836C Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
12/04/2001	CA2158173C Method of treating addictive behaviors
12/02/2001	CA2349388A1 A pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
11/2001
11/29/2001	WO2001090758A2 Diagnosis of alzheimer's disease ldl receptor protein-1
11/29/2001	WO2001090747A2 Modulation of t-cell receptor interactions
11/29/2001	WO2001090421A2 Method of detecting inflammatory lung disorders
11/29/2001	WO2001090404A1 Drug screening systems and assays
11/29/2001	WO2001090390A1 Use of baculovirus vectors in gene therapy
11/29/2001	WO2001090371A1 Mutated eukariotic translation initiation factor 2 alpha kinase 3, eif2ak3, in patients with neonatal insulin-dependent diabetes and multiple epiphyseal dysplasia (wolcott-rallison syndrome)
11/29/2001	WO2001090360A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
11/29/2001	WO2001090359A2 G-protein coupled receptors
11/29/2001	WO2001090334A2 Drug metabolizing enzymes
11/29/2001	WO2001090330A2 AMINOACYL tRNA SYNTHETASES
11/29/2001	WO2001090328A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
11/29/2001	WO2001090251A1 Antimicrobial composition
11/29/2001	WO2001090189A2 G-protein coupled receptor org3.
11/29/2001	WO2001090186A1 Methods for identifying modulators of the interaction between lap (latency associated peptide) and intergrin alpha.v.beta.3 and medical use thereof
11/29/2001	WO2001090159A2 Compositions and methods for delivery of a molecule into a cell
11/29/2001	WO2001090148A2 Neurotransmitter transporters
11/29/2001	WO2001090139A2 A ligand for enhancing oral and cns delivery of biological agents
11/29/2001	WO2001090101A1 Arylmethylamine derivatives for use as tryptase inhibitors
11/29/2001	WO2001090074A2 BENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a)
11/29/2001	WO2001089589A1 A novel treatment for cough
11/29/2001	WO2001089577A2 Conjugates of aminodrugs comprising an oxime bond
11/29/2001	WO2001089570A2 Combination of growth hormone secretagogues and antidepressants
11/29/2001	WO2001089569A1 Combinations of enzyme inhibitor-containing preparations and the use thereof
11/29/2001	WO2001089566A1 Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
11/29/2001	WO2001089564A2 Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
11/29/2001	WO2001089556A1 Inhibition of smad3 to prevent fibrosis and improve wound healing
11/29/2001	WO2001089554A2 Treatment of acute coronary syndrome with glp-1
11/29/2001	WO2001089552A1 Modulaton of alpha-6 integrin-mediated responses
11/29/2001	WO2001089545A1 Antiviral methods and compositions
11/29/2001	WO2001089531A1 Crystal structures of p- selectin,ep0105895-selectin complexes, and uses thereof
11/29/2001	WO2001089530A2 Combination therapy for treatment of depression comprising an antidepressant and an ampa receptor potentiator
11/29/2001	WO2001089526A1 Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
11/29/2001	WO2001089525A1 Combination of cerivastatin with ace inhibitors and the use thereof in medicaments
11/29/2001	WO2001089520A2 Dehydroascorbic acid formulations and uses thereof
11/29/2001	WO2001089519A1 Thromboxane inhibitors, compositions and methods of use related applications
11/29/2001	WO2001089514A2 Pharmaceutical composition comprising a free-radical scavenging sedative agent and a metal ion chelating agent
11/29/2001	WO2001089509A2 Method of treating hiv-1 disease
11/29/2001	WO2001089502A2 Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes
11/29/2001	WO2001089501A1 Polymerizable compositions and methods of use
11/29/2001	WO2001089499A2 Use of pyridinylimidazole carbamate derivate for the manufacture of a medicament for the treatment of cancer
11/29/2001	WO2001089496A2 Compositions and methods for treating otic, ophthalmic and nasal infections comprising quinolone antibiotics
11/29/2001	WO2001089495A2 Antibiotic compositions containing quinolone derivatives for treatment of the eye, ear and nose
11/29/2001	WO2001089490A1 Dosage of transdermal delivery systems
11/29/2001	WO2001089486A1 Nonoral preparation having three-layer structure
11/29/2001	WO2001089479A2 Sustained release pharmaceutical compositions for parenteral administration of hydrophilic compounds
11/29/2001	WO2001089467A1 Composition containing at least one aryl oxime and at least one active substance for treating acne and the use thereof
11/29/2001	WO2001089457A2 Thrombopoietin mimetics
11/29/2001	WO2001089448A2 Combination of adrenergic agonist and nmda antagonist for relieving chronic pain without adverse side effects
11/29/2001	WO2001089435A1 Methods of pre-selecting a polymerizable fluid formed into an intraocular lens
11/29/2001	WO2001089303A1 Methods of modulating the activity of mura
11/29/2001	WO2001066096A3 Compositions for prevention and treatment of dementia
11/29/2001	WO2001044465A3 Therapeutically useful synthetic oligonucleotides
11/29/2001	WO2001044272A3 Daptomycin analogs as antibacterial agents
11/29/2001	WO2001040451A3 Masp-3, a complement-fixing enzyme, and uses for it
11/29/2001	WO2001040309A3 Anti-prostate stem cell antigen (psca) antibody compositions and methods of use
11/29/2001	WO2001031007A3 Nucleic acid molecules derived from rat brain and programmed cell death models
11/29/2001	WO2001025433A3 Novel polypeptides, their nucleic acids, and methods for their use in angiogenesis and vascularization
11/29/2001	WO2001023590A3 22196, a novel human aminopeptidase
11/29/2001	WO2001019776A3 Novel derivatives of dicarboxylic acid having pharmaceutical properties
11/29/2001	WO2001017550A3 Vaccine against hbv and hpv
11/29/2001	WO2001000864A3 Nucleic acid binding of multi-zinc finger transcription factors
11/29/2001	WO2000073469A3 Protein kinases
11/29/2001	WO2000061597A9 Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin

1 ... 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 ... 1151